Payment overview · 2025
General Payments
$1,383.75
73 reported records · 22 companies
Healthcare provider profile · identity verified
Laura C Vance, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BOLIVAR, MO · NPI 1225050784
Verified facts
What the public records show
CMS Open Payments records show Laura C Vance, M.D. received $1,383.75 in general payments during 2025 across 73 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 12.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Qulipta, Rybelsus, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ubrelvy by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $174.55 | 12.6% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $150.73 | 10.9% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $143.87 | 10.4% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $134.85 | 9.8% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $124.98 | 9.0% | 7 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $82.14 | 5.9% | 4 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $75.96 | 5.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $73.32 | 5.3% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $60.70 | 4.4% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $56.56 | 4.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $43.65 | 3.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $43.61 | 3.1% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $42.17 | 3.0% | 3 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $34.27 | 2.5% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.73 | 2.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.96 | 1.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.80 | 1.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.06 | 1.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.20 | 1.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.36 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.86 | 1.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.42 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,383.75 | 73 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $174.55 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $134.60 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $124.98 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $111.33 | 5 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $82.14 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $80.33 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $80.30 | 7 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $75.96 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $75.64 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $73.32 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $72.46 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $63.57 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $63.57 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $56.68 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $56.56 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $43.61 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $34.27 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $34.27 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.84 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.21 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $28.08 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $27.73 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 155 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 46 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 76 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 179 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
58 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
54 | 54 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
126 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
214 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
76 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
179 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
155 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1042 | 253 |
| Lisinopril | Lisinopril | 669 | 180 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 643 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 567 | 132 |
| Omeprazole | Omeprazole | 553 | 153 |
| Levothyroxine Sodium | Levothyroxine Sodium | 531 | 127 |
| Potassium Chloride | Potassium Chloride | 455 | 108 |
| Gabapentin | Gabapentin | 441 | 114 |
| Tramadol Hcl | Tramadol Hcl | 411 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 400 | 103 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 330 | 94 |
| Losartan Potassium | Losartan Potassium | 327 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 293 | 76 |
| Furosemide | Furosemide | 237 | 67 |
| Alprazolam | Alprazolam | 232 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 231 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 71 |
| Jardiance | Empagliflozin | 214 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 205 | 70 |
| Metformin Hcl | Metformin Hcl | 200 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 199 | 51 |
| Tizanidine Hcl | Tizanidine Hcl | 188 | 75 |
| Trazodone Hcl | Trazodone Hcl | 181 | 51 |
| Ozempic | Semaglutide | 179 | 39 |
| Oxycodone Hcl | Oxycodone Hcl | 173 | 29 |
| Eliquis | Apixaban | 155 | 44 |
| Spironolactone | Spironolactone | 154 | 33 |
| Metformin Hcl Er | Metformin Hcl | 150 | 43 |
| Cephalexin | Cephalexin | 149 | 77 |
| Sertraline Hcl | Sertraline Hcl | 149 | 35 |
| Bupropion Xl | Bupropion Hcl | 140 | 31 |
| Alendronate Sodium | Alendronate Sodium | 139 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 139 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 136 | 39 |
| Simvastatin | Simvastatin | 128 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 126 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 126 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 115 | 27 |
| Pregabalin | Pregabalin | 112 | 18 |
| Buspirone Hcl | Buspirone Hcl | 111 | 35 |
| Famotidine | Famotidine | 106 | 36 |
| Montelukast Sodium | Montelukast Sodium | 106 | 34 |
| Carvedilol | Carvedilol | 105 | 27 |
| Glimepiride | Glimepiride | 104 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 99 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 34 |
| Celecoxib | Celecoxib | 97 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 31 |
| Lorazepam | Lorazepam | 93 | 18 |
| Allopurinol | Allopurinol | 90 | 16 |
| Fluconazole | Fluconazole | 90 | 41 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 23 |
| Ezetimibe | Ezetimibe | 81 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 76 | 16 |
| Mounjaro | Tirzepatide | 76 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 22 |
| Morphine Sulfate Er | Morphine Sulfate | 75 | suppressed |
| Clonazepam | Clonazepam | 74 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 74 | 58 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 71 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 14 |
| Hydromorphone Hcl | Hydromorphone Hcl | 68 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 66 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 20 |
| Lovastatin | Lovastatin | 61 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 18 |
| Linzess | Linaclotide | 58 | 17 |
| Nystatin | Nystatin | 57 | 15 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 54 | 54 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 13 |
| Ondansetron Odt | Ondansetron | 53 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 15 |
| Meloxicam | Meloxicam | 52 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | 15 |
| Atenolol | Atenolol | 50 | 13 |
| Temazepam | Temazepam | 50 | suppressed |
| Baclofen | Baclofen | 49 | 11 |
| Meclizine Hcl | Meclizine Hcl | 48 | 13 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 46 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 45 | suppressed |
| Valsartan | Valsartan | 45 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | suppressed |
| Topiramate | Topiramate | 44 | 13 |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 43 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 43 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 42 | 18 |
| Methenamine Hippurate | Methenamine Hippurate | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 20 |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 36 | 17 |
| Colestipol Hcl | Colestipol Hcl | 36 | suppressed |
| Diazepam | Diazepam | 36 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | 12 |
| Bumetanide | Bumetanide | 34 | suppressed |
| Prednisone | Prednisone | 34 | 17 |
| Carisoprodol | Carisoprodol | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Fentanyl | Fentanyl | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Lidocaine | Lidocaine | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 27 | suppressed |
| Myrbetriq | Mirabegron | 26 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 26 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 26 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Ingrezza | Valbenazine Tosylate | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Estradiol | Estradiol | 23 | 13 |
| Methadone Hcl | Methadone Hcl | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | 11 |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Insulin Lispro | Insulin Lispro | 20 | suppressed |
| Modafinil | Modafinil | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 14 |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Ubrelvy | Ubrogepant | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Roflumilast | Roflumilast | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Epinephrine | Epinephrine | 16 | 13 |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 11 |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 13 | 12 |
| Nitroglycerin | Nitroglycerin | 13 | 12 |
| Qulipta | Atogepant | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Trandolapril | Trandolapril | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,383.75 · 73 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AIRSUPRA, ARISTADA, AUSTEDO XR, BREZTRI, CAPLYTA, CAPVAXIVE, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FANAPT, FARXIGA, FREESTYLE LIBRE, GARDASIL 9, LEQVIO, LYBALVI, Leqembi, MOUNJARO, NURTEC ODT, Ozempic, PROLIA, QULIPTA, REXULTI, Rybelsus, SHINGRIX, Senza, Tymlos, UBRELVY, UZEDY, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error